Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/51331
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Clinical significance of anti-HLA antibodies detected by Luminex®: enhancing the interpretation of CDC-BXM and important post-transplantation monitoring tools |
Other Titles: | Clinical significance of anti-HLA antibodies detected by Luminex (R): enhancing the interpretation of CDC-BXM and important post-transplantation monitoring tools |
Author: | Eng, H. Bennett, G. Bardy, P. Lau, X. Russ, G. Coates, P. |
Citation: | Human Immunology, 2009; 70(8 Sp Iss):595-599 |
Publisher: | Elsevier Science Inc |
Issue Date: | 2009 |
ISSN: | 0198-8859 1879-1166 |
Statement of Responsibility: | Hooi Sian Eng, Greg Bennett, Peter Bardy, Patrick Coghlan, Graeme R. Russ, P. Toby H. Coates |
Abstract: | B-cell crossmatch (BXM) was originally introduced to increase the sensitivity to detect anti-HLA antibodies of conventional CDC crossmatch in renal transplantation. Newer techniques such as Luminex((R)) have greater sensitivity in detecting anti-HLA antibodies but have not been directly evaluated versus BXM. We discuss our experience with Luminex testing and the significance of donor-specific antibodies (DSA) defined by Luminex in three populations, as compared with the CDC crossmatch. In the general transplant population, Luminex-defined DSA were found in only one third of positive CDC-BXM and were associated with graft rejection. Luminex testing enhanced the interpretation of CDC-BXM and identified patients with clinically relevant BXM. In the highly sensitized transplant population, Luminex-defined DSA were found in two thirds of positive BXM and were a better predictor of graft rejection. Therefore, Luminex assays rather than CDC-BXM should be used to facilitate kidney allocation in highly sensitized patients. In the post-transplantation population, Luminex antibody monitoring for DSA was shown to be important, as it defined low-level de novo DSA that were associated with development of transplant glomerulopathy and a significant predictor of graft loss in those patients. Thus Luminex testing facilitated the interpretation of CDC-BXM and provided a useful predictive tool for the detection of clinically significant DSA in post-transplantation antibody monitoring. |
Keywords: | HLA antibodies Luminex® Crossmatch Renal transplantation Monitoring |
DOI: | 10.1016/j.humimm.2009.06.010 |
Published version: | http://dx.doi.org/10.1016/j.humimm.2009.06.010 |
Appears in Collections: | Aurora harvest Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.